This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Rights & Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Schellong, G. Articles by Schwarze, E.-W. Search for Related Content PubMed PubMed Citation Articles by Schellong, G. Articles by Schwarze, E.-W. Social Bookmarking                            What's this?

High Cure Rates and Reduced Long-Term Toxicity in Pediatric Hodgkin's Disease: The German-Austrian Multicenter Trial DAL-HD-90

From the Department of Pediatric Hematology and Oncology, University Children's Hospital; Department of Radiotherapy and Radiooncology, University of Münster, Münster; Paracelsus Radiation Hospital, Osnabrück; II. Children's Hospital, Berlin-Buch; Department of Pediatric Hematology and Oncology, University Children's Hospital, Düsseldorf; Children's Hospital of the Medical School, Hannover; University Children's Hospital, Dresden; Institute for Hematopathology and Lymph Node Registry of the German Association of Pathologists, University of Kiel, Kiel; Municipal Institute for Pathology, Dortmund, Germany; Department of Radiotherapy, University of Vienna; and the St Anna Children's Hospital, Vienna, Austria.

Address reprint requests to Günther Schellong, MD, Univ.-Kinderklinik, Albert-Schweitzer-Straße 33, D-48129 Münster, Germany; email schellon{at}uni-muenster.de

PURPOSE: To further reduce therapy-related late effects in patients with pediatric Hodgkin's disease (HD) while maintaining the high cure rates achieved with vincristine, prednisone, procarbazine, and doxorubicin (OPPA) or OPPA/cyclophosphamide, vincristine, prednisone, and procarbazine (COPP) chemotherapy and involved-field radiotherapy. The risk of testicular dysfunction was addressed by substituting etoposide for procarbazine (OEPA) in the induction therapy for boys. Radiation doses and fields were further reduced.

PATIENTS AND METHODS: Three hundred nineteen boys and 259 girls younger than 18 years with previously untreated HD, enrolled onto the study between 1990 and 1995, were allocated to treatment group (TG)1 (early stages), TG2 (intermediate stages), or TG3 (advanced stages). All groups underwent two cycles of OEPA (boys) or OPPA (girls) for induction chemotherapy. TG2 and TG3 continued on additional two or four cycles, respectively, of COPP. Low-dose radiotherapy was given to the initially involved sites, ie, reduced involved fields.

RESULTS: Initial response to OPPA or OEPA induction was virtually identical. Eight of 578 patients experienced early progression of HD. Thirty-seven relapses, three secondary tumors, and no secondary leukemias have been recorded, with a median follow-up duration of 5.1 years (maximum, 8.1 years). Thirteen of 578 patients died. The probability of 5-year event-free survival/overall survival is 91%/98% in the total group, 94%/97% with OPPA, and 89%/98% with OEPA induction therapy. Risk factor analysis showed two significant prognostic factors: histologic subtype NS2 and "B" symptoms. OEPA induction therapy, large mediastinal tumor, and age were not significant. Preliminary studies of testicular function indicate a lower risk of germ cell damage than previously documented with OPPA.

CONCLUSION: OEPA is a satisfactory alternative to OPPA. Radiotherapy can be confined to involved sites when combined with appropriate chemotherapy. The DAL-HD-90 regimen represents a comprehensive treatment program for all stages of pediatric HD and offers a favorable benefit/risk ratio, combining excellent disease control, moderate acute toxicity, and reduced long-term toxicity.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				L. A. Jacobs, S. C. Palmer, L. A. Schwartz, A. DeMichele, J. J. Mao, J. Carver, C. Gracia, C. E. Hill-Kayser, J. M. Metz, M. K. Hampshire, et al. Adult Cancer Survivorship: Evolution, Research, and Planning Care CA Cancer J Clin, November 1, 2009; 59(6): 391 - 410. [Abstract] [Full Text] [PDF]

				A. Claviez, C. Canals, D. Dierickx, J. Stein, I. Badell, A. Pession, S. Mackinnon, S. Slavin, J.-H. Dalle, M. J. Chacon, et al. Allogeneic hematopoietic stem cell transplantation in children and adolescents with recurrent and refractory Hodgkin lymphoma: an analysis of the European Group for Blood and Marrow Transplantation Blood, September 3, 2009; 114(10): 2060 - 2067. [Abstract] [Full Text] [PDF]

				A. T. Meadows and A. M. Leahey More About Second Cancers After Retinoblastoma J Natl Cancer Inst, December 17, 2008; 100(24): 1743 - 1745. [Full Text] [PDF]

				A. T. Meadows Pediatric Cancer Survivorship: Research and Clinical Care J. Clin. Oncol., November 10, 2006; 24(32): 5160 - 5165. [Abstract] [Full Text] [PDF]

				L. M. Foltz, K. W. Song, and J. M. Connors Hodgkin's Lymphoma in Adolescents J. Clin. Oncol., June 1, 2006; 24(16): 2520 - 2526. [Abstract] [Full Text] [PDF]

				M. Alebouyeh, F. Moussavi, H. Haddad-Deylami, and P. Vossough Successful ambulatory treatment of Hodgkin's disease in Iranian children based on German-Austrian DAL-HD 85-90: single institutional results Ann. Onc., December 1, 2005; 16(12): 1936 - 1940. [Abstract] [Full Text] [PDF]

				G. Schellong, W. Dorffel, A. Claviez, D. Korholz, G. Mann, H.-G. Scheel-Walter, J. P.M. Bokkerink, M. Riepenhausen, H. Luders, R. Potter, et al. Salvage Therapy of Progressive and Recurrent Hodgkin's Disease: Results From a Multicenter Study of the Pediatric DAL/GPOH-HD Study Group J. Clin. Oncol., September 1, 2005; 23(25): 6181 - 6189. [Abstract] [Full Text] [PDF]

				A. Claviez, M. Tiemann, H. Luders, M. Krams, R. Parwaresch, G. Schellong, and W. Dorffel Impact of Latent Epstein-Barr Virus Infection on Outcome in Children and Adolescents With Hodgkin's Lymphoma J. Clin. Oncol., June 20, 2005; 23(18): 4048 - 4056. [Abstract] [Full Text] [PDF]

				M. M. Hudson, M. Krasin, M. P. Link, S. S. Donaldson, C. Billups, T. E. Merchant, L. Kun, A. L. Billet, S. Kaste, N. J. Tarbell, et al. Risk-Adapted, Combined-Modality Therapy With VAMP/COP and Response-Based, Involved-Field Radiation for Unfavorable Pediatric Hodgkin's Disease J. Clin. Oncol., November 15, 2004; 22(22): 4541 - 4550. [Abstract] [Full Text] [PDF]

				R. S. Smith, Q. Chen, M. M. Hudson, M. P. Link, L. Kun, H. Weinstein, A. Billett, K. J. Marcus, N. J. Tarbell, and S. S. Donaldson Prognostic Factors for Children With Hodgkin's Disease Treated With Combined-Modality Therapy J. Clin. Oncol., May 15, 2003; 21(10): 2026 - 2033. [Abstract] [Full Text] [PDF]

				K. C.M. Straathof, C. M. Bollard, C. M. Rooney, and H. E. Heslop Immunotherapy for Epstein-Barr Virus-Associated Cancers in Children Oncologist, February 1, 2003; 8(1): 83 - 98. [Abstract] [Full Text] [PDF]

				O. Oberlin When Quality of Life Is the Major Challenge J. Clin. Oncol., July 15, 2002; 20(14): 3051 - 3053. [Full Text] [PDF]

				A. M. Friedmann, M. M. Hudson, H. J. Weinstein, S. S. Donaldson, L. Kun, N. J. Tarbell, and M. P. Link Treatment of Unfavorable Childhood Hodgkin's Disease With VEPA and Low-Dose, Involved-Field Radiation J. Clin. Oncol., July 15, 2002; 20(14): 3088 - 3094. [Abstract] [Full Text] [PDF]